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Introduction 
Myopathy affects 1-5% of patients 
prescribed statin medications1 and less than 
1% of patients prescribed fibric acid 
derivatives.2 Fish oil has been used to 
alleviate statin-induced myopathy. No 
known cases of fish oil-induced myopathy 
have been reported.3 Our case of fish oil-
induced myopathy was confirmed by 
repeated symptomatology and elevation in 
creatine kinase with reintroduction of fish 
oil supplement for hypertriglyceridemia 
treatment. 
 
Case Report 
A 47-year-old male was referred to an 
endocrinology clinic for management of 
hypertriglyceridemia.  He felt well and had 
no history of pancreatitis or xanthomata. His 
past medical history was significant for 
anxiety, depression, gastroesophageal reflux 
disease, and hypertension.   Medications 
included alprazolam, sertraline, omeprazole, 
and amlodipine/benazepril.   
Fasting measurement of serum lipids 
revealed a total cholesterol level of 195 
mg/dL, triglyceride level of 722 mg/dl, and 
high-density lipoprotein level of 34 mg/dL. 
His low-density lipoprotein level was not 
calculated. Thyroid stimulating hormone 
was 1.28 uIU/mL (reference range 0.40-
4.10).  A two-hour 75 gram oral glucose 
tolerance test revealed a fasting serum 
glucose of 88 mg/dl and a two-hour value of 
 
 
 
 
102 mg/dL. Serum electrolytes and a 
complete blood count were unremarkable. 
The patient was placed on generic fish 
oil at a dose of 2 grams orally twice daily 
along with fenofibrate 145 mg orally daily. 
After two weeks, he reported muscle pain in 
his back and thighs bilaterally. The 
discomfort was not associated with 
increased physical activity. His serum 
creatinine kinase (CK) level was elevated at 
340 U/L (reference range 32-237).  Serum 
electrolytes were unremarkable.  The fish oil 
and fenofibrate were discontinued. His 
muscle discomfort resolved. 
Fish oil was reintroduced three weeks 
later at 2 grams orally twice daily. 
Fenofibrate was not restarted.  Within two 
weeks, his muscle pain returned. Serum 
creatinine kinase level again was elevated at 
268 U/L.  A fasting lipid panel revealed a 
total cholesterol level of 259 mg/dL, 
triglycerides of 1180 mg/dL, and a high-
density lipoprotein level of 34 mg/dL.  The 
fish oil was discontinued, and his muscle 
symptoms resolved.  Serum creatine kinase 
level one month later was normal at 159 
U/L. 
 
Discussion 
The mechanism of myopathy associated 
with statins and fibric acid derivatives is 
poorly understood.  Possible mechanisms for 
statins include reduced levels of ubiquinone, 
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reduced guanosine triphosphate (GTP)–
binding regulatory proteins, or altered 
phospholipid metabolism.1  Muscle toxicity 
has been associated with increased systemic 
or tissue statin levels, affected by gene 
mutations4, drug dose, co-administration of 
gemfibrozil, and grapefruit1.  
The proposed mechanisms of fibrate-
associated myopathy are even less clear, but 
also appear to involve genetic 
predisposition, drug interactions, and 
medication dose.2 The etiologies of muscle 
damage with statins and fibrates are unlikely 
to be present with fish oil, whose proposed 
mechanisms of action differ significantly 
from either statins or fibrates.5 The presence 
of diabetes, renal failure, and 
hypothyroidism can contribute to myopathy, 
but none were present in this patient. 
This case demonstrated true myopathy 
with muscle pain and an elevation in CK 
associated with administration of fish oil. 
The initial symptoms resolved with 
discontinuation of fish oil and fenofibrate, 
but muscle pain and an elevated CK 
returned upon re-introduction of fish oil 
alone.  Both resolved within one month of 
discontinuing the fish oil.  A contributing 
factor may have been the type of fish oil 
used, as it was marketed as a nutritional 
supplement, not as a pharmaceutical-grade 
product. 
 
Conclusion 
Fish oil can be associated with myopathy 
either alone or in combination with 
fenofibrate. If signs and symptoms of 
myopathy do not resolve with discon-
tinuation of other antihyperlipidemic agents, 
discontinuation of fish oil should be 
considered.
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